THMO Stock Overview
Develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ThermoGenesis Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0007 |
| 52 Week High | US$1.25 |
| 52 Week Low | US$0.0005 |
| Beta | 2.45 |
| 11 Month Change | 16.67% |
| 3 Month Change | -99.68% |
| 1 Year Change | -99.92% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
It's Down 52% But ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Could Be Riskier Than It Looks
Apr 17
ThermoGenesis reports Q2 results
Aug 11Is ThermoGenesis Holdings (NASDAQ:THMO) Using Too Much Debt?
Oct 20Is ThermoGenesis Holdings (NASDAQ:THMO) A Risky Investment?
May 31When Will ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Become Profitable?
Apr 06Here's Why ThermoGenesis Holdings (NASDAQ:THMO) Can Afford Some Debt
Feb 10Does ThermoGenesis Holdings' (NASDAQ:THMO) CEO Salary Compare Well With Industry Peers?
Dec 15
ThermoGenesis EPS misses by $0.27, misses on revenue
Nov 12Shareholder Returns
| THMO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.0% |
| 1Y | -99.9% | 20.8% | 31.4% |
Return vs Industry: THMO underperformed the US Medical Equipment industry which returned 20.5% over the past year.
Return vs Market: THMO underperformed the US Market which returned 30.7% over the past year.
Price Volatility
| THMO volatility | |
|---|---|
| THMO Average Weekly Movement | 938.6% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: THMO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: THMO's weekly volatility has increased from 428% to 939% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 25 | Chris Xu | www.thermogenesis.com |
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications.
ThermoGenesis Holdings, Inc. Fundamentals Summary
| THMO fundamental statistics | |
|---|---|
| Market cap | US$7.92k |
| Earnings (TTM) | -US$14.74m |
| Revenue (TTM) | US$9.61m |
0.0x
P/S Ratio0.0x
P/E RatioIs THMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THMO income statement (TTM) | |
|---|---|
| Revenue | US$9.61m |
| Cost of Revenue | US$7.58m |
| Gross Profit | US$2.03m |
| Other Expenses | US$16.77m |
| Earnings | -US$14.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 21.10% |
| Net Profit Margin | -153.43% |
| Debt/Equity Ratio | -386.9% |
How did THMO perform over the long term?
See historical performance and comparison